908 Devices (MASS) Canaccord Genuity's 46th Annual Growth Conference summary

Strategic focus and market transition

• Shifted from bioprocessing/biopharma to handheld chemical detection for public safety and defense, following divestiture of the medical device line 15 months ago.

• Emphasizes rapid, field-based chemical analysis to address law enforcement and hazmat needs, reducing forensic lab backlogs and enabling faster case resolution.

• Growth driven by addressing synthetic opioid crises and toxic industrial chemical threats.

• International expansion supported by recent NIRLab acquisition, leveraging a strong sales platform.

Product portfolio and innovation

• MX908 is the flagship, highly sensitive device for synthetic opioids, chemical weapons, and non-traditional agents, with 3,000 units deployed.

• VipIR integrates FTIR and Raman technologies for bulk chemical identification, targeting customs, ports, and hazmat teams.

• NIRLab, acquired recently, offers rapid, cloud-connected drug screening for routine police operations at a lower price point.

• Product prices range from $10,000 (NIRLab) to over $100,000 (VipIR), with deployment scaling from individual officers to large military units.

• Next-generation MX908 in development, aiming for reduced size, weight, and enhanced connectivity.

Regulatory and market drivers

• Legislative changes in several states are phasing out colorimetric kits for drug screening, increasing demand for digital, auditable solutions like NIRLab.

• Cloud connectivity enables real-time trend analysis and fleet management, supporting law enforcement and postal inspection services.

• U.S. and international demand rising due to the global illicit drug crisis, with products tailored to local regulatory needs.